Genome-wide analysis of alternative promoters of human genes using a custom promoter tiling array

Gregory A. C. Singer, Jiejun Wu, Pearlly S. Yan, Christoph Plass, Tim H-m. Huang, Ramana V. DavuluriBMC 2008 · DOI

TL;DR

This paper introduces a novel microarray platform to comprehensively analyze alternative promoter usage across the human genome. They discovered widespread alternative promoter activity, with a surprising tendency for downstream promoters in estrogen-sensitive genes to be located near the 3' end of the gene, suggesting novel regulatory mechanisms.

What Problem Does This Paper Address?

The regulation of gene expression is incredibly complex, and a significant part of this complexity arises from the fact that many human genes don't have just one "start button" (promoter) but multiple. These alternative promoters can initiate transcription at different start sites, leading to various RNA transcripts and ultimately different protein products. Understanding which promoter is active in which cellular context is crucial for deciphering gene regulatory networks and how they go awry in diseases like cancer. Traditional methods for studying gene expression often struggle to distinguish between transcripts originating from different promoters, especially when the differences are subtle. This paper aims to provide a genome-wide view of alternative promoter activity and how it's regulated, particularly in response to hormonal stimuli.

Methods

The core of this work is the development of a custom promoter tiling microarray. This array was designed to interrogate approximately 34,000 putative and known alternative promoters from nearly 7,000 human genes. The probes on the array are 60-mers designed to tile the core promoter regions (-200 to +200 bp around the transcription start site).

To assess promoter activity, the researchers employed Chromatin Immunoprecipitation followed by microarray analysis (ChIP-chip). Specifically, they used an antibody against RNA Polymerase II (RNA Pol II), a key enzyme in transcription initiation. By analyzing the binding of RNA Pol II to promoter regions in MCF7 cells, both with and without 17β-estradiol (E2) treatment, they could infer which promoters were actively being transcribed.

They developed a statistical model (a modified Gamma-Normal mixture model) to classify promoters as "bound" (active) or "unbound" (inactive) based on the ChIP-chip signal, allowing for different confidence levels. This approach was validated using quantitative PCR (ChIP-PCR and qRT-PCR) on a subset of promoters.

Datasets

The primary dataset used in this study is generated by the authors' custom promoter tiling microarray. The design of this array was informed by integrating data from three sources:

  • UCSC Known Genes track: Based on RefSeq mRNA alignments.
  • Riken CAGE tags: Capturing the 5' end of messenger RNAs.
  • FirstEF program: A computational tool for predicting promoter regions.

The experimental data was generated from MCF7 human breast cancer cells, treated with and without 17β-estradiol (E2) for 3 hours.

Key Insights and Ideas

  • Widespread Alternative Promoter Usage: The study reveals that a significant fraction of human genes utilize alternative promoters, contributing substantially to transcriptional complexity.
  • Novel Regulatory Mechanisms: A striking finding is the tendency for downstream promoters in E2-sensitive genes to be located very close to the 3' end of the gene. This is unusual and suggests potential roles beyond simply initiating transcription, possibly involving the regulation of the primary transcript.
  • Promoter Activity and CpG Islands: Consistent with previous findings, upstream promoters are strongly associated with CpG islands, while downstream promoters are much less so. This suggests different regulatory mechanisms and potentially different functional roles.
  • Discovery of Novel Promoters: The research identified a substantial number of active promoters that were not previously annotated, suggesting that current gene annotations may be incomplete, particularly at the 5' end of genes.
  • Estrogen's Differential Impact: E2 treatment primarily leads to the inactivation of promoters rather than activation, and this effect is more pronounced on downstream promoters.

Key Results

  • The custom microarray platform interrogates ~34,000 putative promoters from nearly 7,000 human genes.
  • The median number of promoters per gene on the array is three.
  • At least 65% of promoters are inactive in MCF7 cells, while approximately 17% show strong evidence of activity.
  • Validation experiments confirmed the accuracy of the ChIP-chip predictions for both active and inactive promoters.
  • Out of 212 genes with two active promoters in at least one condition, downstream promoters were more often affected by E2 treatment (62 activated, 64 inactivated) than upstream promoters (25 activated, 61 inactivated).
  • A significant bias was observed: in E2-sensitive genes with two promoters, the downstream promoter was strongly biased towards the 3' end of the gene.

Limitations and Future Work

  • Promoter Function vs. RNA Pol II Binding: While RNA Pol II binding is a strong indicator of promoter activity, it doesn't directly confirm the production of a functional protein-encoding transcript. The authors acknowledge that many identified promoters might not produce meaningful transcripts.
  • Cell-Type Specificity: The study was conducted in MCF7 cells. The activity and regulation of these alternative promoters may differ in other cell types or under different physiological conditions.
  • Mechanisms of 3'-End Promoters: The function and precise regulatory role of the downstream, 3'-end promoters remain speculative. The authors suggest they might act as "blocking" promoters or produce interfering RNAs, but further research is needed to elucidate these mechanisms.
  • Future Directions: The authors propose that their microarray platform is versatile and can be adapted for other epigenomic studies (e.g., methylation) and for profiling other transcription factors or histone modifications. They also highlight the need for further work to understand the regulatory actions of these 3'-UTR promoters.

Summary updated

Abstract

The usage of alternative promoters greatly multiplies the transcriptional complexity available within the human genome. The fact that many of these promoters are incapable of driving the synthesis of a meaningful protein-encoding transcript further complicates the story.
BibTeX
@inproceedings{singer2008genome,
  author = {Gregory A. C. Singer and Jiejun Wu and Pearlly S. Yan and Christoph Plass and Tim H-M. Huang and Ramana V. Davuluri},
  title = {{Genome-wide analysis of alternative promoters of human genes using a custom promoter tiling array}},
  booktitle = {BMC},
  year = {2008},
  doi = {10.1186/1471-2164-9-349},
}
Figure